Teladoc Health, Inc. (NYSE:TDOC) Stock Holdings Lifted by Point72 Asia Singapore Pte. Ltd.

Point72 Asia Singapore Pte. Ltd. boosted its stake in shares of Teladoc Health, Inc. (NYSE:TDOC) by 112.8% during the third quarter, HoldingsChannel.com reports. The firm owned 14,664 shares of the health services provider’s stock after acquiring an additional 7,773 shares during the period. Point72 Asia Singapore Pte. Ltd.’s holdings in Teladoc Health were worth $135,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in TDOC. Rubric Capital Management LP purchased a new position in Teladoc Health during the second quarter valued at approximately $45,267,000. Point72 Asset Management L.P. grew its position in Teladoc Health by 221.9% during the second quarter. Point72 Asset Management L.P. now owns 5,303,123 shares of the health services provider’s stock valued at $51,865,000 after purchasing an additional 3,655,436 shares in the last quarter. Clearline Capital LP grew its position in Teladoc Health by 395.6% during the second quarter. Clearline Capital LP now owns 4,364,201 shares of the health services provider’s stock valued at $42,682,000 after purchasing an additional 3,483,665 shares in the last quarter. Assenagon Asset Management S.A. purchased a new position in Teladoc Health during the third quarter valued at approximately $15,801,000. Finally, Mizuho Markets Americas LLC purchased a new position in Teladoc Health during the second quarter valued at approximately $3,937,000. 76.82% of the stock is owned by hedge funds and other institutional investors.

Teladoc Health Trading Down 2.0 %

Shares of TDOC stock opened at $10.80 on Friday. Teladoc Health, Inc. has a 1 year low of $6.76 and a 1 year high of $22.54. The firm’s fifty day simple moving average is $9.58 and its 200 day simple moving average is $9.23. The firm has a market capitalization of $1.86 billion, a P/E ratio of -1.87 and a beta of 0.97. The company has a current ratio of 1.73, a quick ratio of 1.69 and a debt-to-equity ratio of 0.66.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings results on Wednesday, October 30th. The health services provider reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.10. The firm had revenue of $640.51 million for the quarter, compared to analyst estimates of $630.50 million. Teladoc Health had a negative net margin of 37.91% and a negative return on equity of 10.06%. As a group, sell-side analysts predict that Teladoc Health, Inc. will post -1.16 EPS for the current year.

Insider Buying and Selling at Teladoc Health

In other news, Director Thomas Mckinley bought 4,000 shares of the stock in a transaction dated Thursday, September 12th. The shares were acquired at an average price of $7.69 per share, with a total value of $30,760.00. Following the acquisition, the director now owns 39,077 shares in the company, valued at $300,502.13. This trade represents a 11.40 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Carlos Nueno sold 2,389 shares of the company’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $11.93, for a total transaction of $28,500.77. Following the completion of the sale, the insider now directly owns 2,890 shares in the company, valued at approximately $34,477.70. The trade was a 45.25 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.95% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on TDOC shares. Barclays boosted their price objective on shares of Teladoc Health from $10.00 to $12.00 and gave the company an “overweight” rating in a research report on Thursday, October 31st. Piper Sandler reiterated an “overweight” rating and issued a $13.00 target price (up from $11.00) on shares of Teladoc Health in a research note on Wednesday. Royal Bank of Canada lifted their target price on shares of Teladoc Health from $9.00 to $10.00 and gave the company an “outperform” rating in a research note on Wednesday, October 9th. Jefferies Financial Group lifted their target price on shares of Teladoc Health from $8.00 to $10.00 and gave the company a “hold” rating in a research note on Tuesday, September 17th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Teladoc Health from $16.00 to $9.00 and set a “neutral” rating for the company in a research note on Monday, August 26th. Fourteen investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $12.24.

Teladoc Health Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.